68Ga-MY6349 PET/CT in Solid Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital of Xiamen University
About this trial
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET/CT.
Eligibility criteria
Qualifiers
adult patients (aged 18 years or older)
patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)
patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET/CT scans
patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee
Disqualifiers
patients with pregnancy
the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent
Trial design
Treatments tested in this trial
- 68Ga-MY6349
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov